Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Income towards Parent Company (2022 - 2025)

Historic Income towards Parent Company for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$4.3 million.

  • Atara Biotherapeutics' Income towards Parent Company rose 8035.97% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.4 million, marking a year-over-year increase of 11754.08%. This contributed to the annual value of -$85.4 million for FY2024, which is 6909.89% up from last year.
  • Latest data reveals that Atara Biotherapeutics reported Income towards Parent Company of -$4.3 million as of Q3 2025, which was up 8035.97% from $2.4 million recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year Income towards Parent Company high stood at $38.0 million for Q1 2025, and its period low was -$88.1 million during Q1 2022.
  • Moreover, its 4-year median value for Income towards Parent Company was -$31.8 million (2024), whereas its average is -$36.9 million.
  • In the last 5 years, Atara Biotherapeutics' Income towards Parent Company plummeted by 48507.53% in 2023 and then skyrocketed by 21970.9% in 2025.
  • Atara Biotherapeutics' Income towards Parent Company (Quarter) stood at -$74.7 million in 2022, then grew by 18.72% to -$60.7 million in 2023, then skyrocketed by 79.09% to -$12.7 million in 2024, then skyrocketed by 66.1% to -$4.3 million in 2025.
  • Its Income towards Parent Company stands at -$4.3 million for Q3 2025, versus $2.4 million for Q2 2025 and $38.0 million for Q1 2025.